CJC-1295 + Ipamorelin

Research Benefits

• Synergistic GH Stimulation: Combines GHRH analog (CJC-1295) with a selective GHRP (Ipamorelin) for amplified, physiological growth hormone release through dual-pathway activation
• Pulsatile GH Release: Research demonstrates more natural GH secretion patterns compared to single-agent protocols, mimicking endogenous pulsatility
• IGF-1 Elevation: Combined action produces sustained IGF-1 elevation through both direct GH stimulation and extended GHRH receptor activation
• Body Composition Research: Investigated for favorable changes in lean mass and adipose tissue ratios without significant effects on cortisol or prolactin
• Sleep Architecture: Studies suggest enhanced slow-wave sleep duration, aligning with the natural nocturnal GH pulse

Mechanism of Action

This combination activates two complementary pathways in the GH axis:

CJC-1295 (GHRH Analog)

• Binds GHRH receptors on somatotroph cells in the anterior pituitary
• Stimulates cAMP/PKA signaling cascade for GH gene transcription and release
• No-DAC version provides pulsatile stimulation without sustained receptor activation

Ipamorelin (Selective GHRP)

• Activates ghrelin/GHS-R1a receptors on somatotrophs through a separate signaling pathway
• Highly selective for GH release without significant cortisol, prolactin, or appetite stimulation
• Amplifies CJC-1295's signal through receptor crosstalk and intracellular signaling convergence

The dual-pathway activation produces greater GH release than either peptide alone, while Ipamorelin's selectivity maintains a clean hormonal profile without the side effects associated with less selective GHRPs.

Research Protocol

For research purposes only. Not for human consumption.

• Typical Research Dose: 100-300 mcg CJC-1295 + 100-300 mcg Ipamorelin per administration
• Administration: Subcutaneous injection
• Timing: Pre-sleep administration in most protocols to synergize with natural nocturnal GH pulsatility
• Research Cycle: 8-12 week protocols commonly reported
• Frequency: 1-3 times daily depending on study objectives; once pre-sleep is most common

Reconstitution

• Reconstitute with bacteriostatic water; gently swirl
• Both peptides co-lyophilized for convenient single reconstitution
• Refrigerate at 2-8 °C; use within 30 days

Safety & Storage

• Lyophilized: -20 °C long-term; 2-8 °C up to 6 months
• Reconstituted: 2-8 °C; use within 30 days
• Protect from light and temperature fluctuations

Research Considerations

• Ipamorelin's selectivity minimizes cortisol and prolactin elevation compared to GHRP-6 or GHRP-2 combinations
• Fasting state during administration may enhance GH response; glucose and fatty acids blunt GH secretion
• Long-term GH elevation protocols require monitoring of IGF-1 levels and glucose homeostasis
• Not recommended with somatostatin analogs (opposing mechanism)
• For research use only

Frequently Asked Questions

• Why combine CJC-1295 with Ipamorelin?

  They activate separate receptor pathways on the same pituitary cells, producing synergistic GH release. CJC-1295 provides the GHRH signal while Ipamorelin amplifies it through ghrelin receptor activation, with the added benefit of Ipamorelin's clean selectivity profile.

• Is this the DAC or no-DAC version of CJC-1295?

  BeaCapra's blend uses CJC-1295 without DAC (Drug Affinity Complex), providing pulsatile rather than sustained GH stimulation for a more physiological release pattern.

• Why is pre-sleep dosing preferred?

  The largest natural GH pulse occurs during early slow-wave sleep. Pre-sleep administration synergizes with this endogenous rhythm, amplifying the natural peak rather than creating non-physiological daytime spikes.

• What purity is this product?

  ≥99% purity for both peptides, verified by HPLC and mass spectrometry. COA available.